Cytosorbents/CTSO

$0.88

8.51%
-
1D1W1MYTD1YMAX

About Cytosorbents

CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Company’s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.

Ticker

CTSO

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Phillip Chan

Employees

186

Headquarters

Princeton, United States

Cytosorbents Metrics

BasicAdvanced
$43.99M
Market cap
-
P/E ratio
-$0.64
EPS
0.62
Beta
-
Dividend rate
$43.99M
0.62374
$4.29
$0.78
103.53K
1.767
1.514
10.925
21.666
-48.94%
-97.21%
-61.82%
1.21
1.888
1.89
4.79%
15.37%
-3.94%

What the Analysts think about Cytosorbents

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 5 analysts.
320.45% upside
High $6.50
Low $1.00
$0.88
Current price
$3.70
Average price target

Cytosorbents Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-67.44% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$8.6M
-2.27%
Net income
$-5.8M
-36.26%
Profit margin
-67.44%
-34.78%

Cytosorbents Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.45%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.17
-$0.14
-$0.21
-$0.13
-
Expected
-$0.13
-$0.11
-$0.14
-$0.14
-$0.12
Surprise
34.21%
24.44%
52.17%
-5.45%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Cytosorbents stock?

Cytosorbents (CTSO) has a market cap of $43.99M as of April 24, 2024.

What is the P/E ratio for Cytosorbents stock?

The price to earnings (P/E) ratio for Cytosorbents (CTSO) stock is 0 as of April 24, 2024.

Does Cytosorbents stock pay dividends?

No, Cytosorbents (CTSO) stock does not pay dividends to its shareholders as of April 24, 2024.

When is the next Cytosorbents dividend payment date?

Cytosorbents (CTSO) stock does not pay dividends to its shareholders.

What is the beta indicator for Cytosorbents?

Cytosorbents (CTSO) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Cytosorbents stock price target?

The target price for Cytosorbents (CTSO) stock is $3.7, which is 320.45% above the current price of $0.88. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Cytosorbents stock

Buy or sell Cytosorbents stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing